Moderna, Inc. Common Stock
MRNAModerna, Inc. (MRNA) is a biotechnology company specializing in messenger RNA (mRNA) technology to develop vaccines and therapeutics. Founded in 2010, it gained prominence with its COVID-19 vaccine, playing a key role in the global response to the pandemic. Moderna focuses on innovative mRNA solutions for infectious diseases, cancer, rare diseases, and other conditions.
Company News
Markets traded cautiously on Tuesday despite benign inflation data (CPI at 2.7% YoY, core CPI at 2.6%) that supported Fed rate cut expectations. Silver surged 4.5% to $89/oz amid supply concerns. Major indices remained flat with the S&P 500 near record highs. Earnings results were mixed: JPMorgan fell 3% on weak investment banking fees, Delta sli...
A Motley Fool analyst recommends five stocks for early 2026 portfolio diversification: Amazon (AI and cloud computing leadership), Eli Lilly (weight loss drug market growth), Chewy (pet e-commerce with recurring revenue), Apple (AI features and services growth), and Moderna (biotech recovery story with pipeline expansion). Four stocks have proven...
The global nanobiotechnology market is projected to grow from USD 172.81 billion in 2024 to USD 420.2 billion by 2034, driven by healthcare demand, R&D funding, and technological innovations in drug delivery and medical applications.
Pharmaceutical stocks rallied after Pfizer reached an agreement with the Trump administration to sell drugs at significant discounts, avoiding potential 100% tariffs. Multiple pharma companies saw substantial stock price increases.
Merck's stock has underperformed the industry, sector, and S&P 500 this year due to various challenges, including the upcoming patent expiration of its blockbuster drug Keytruda in 2028 and declining sales of its Gardasil vaccine in China. However, the company has a promising pipeline and new products that could drive long-term growth.
